Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2017

View Archived Issues

WAVE Life Sciences receives FDA orphan designation for WVE-120102

FDA gives orphan drug status to ProQR Therapeutics' QR-313 for dystrophic epidermolysis bullosa

Novavax begins study of NanoFlu vaccine in older adults

FGFR-1/beta-klotho bispecific antibody shows benefit in obese subjects

Reduced blood glucose and insulin doses seen with GCGR antibody REMD-477 in type 1 diabetes patients

Asahi Glass describes novel influenza vaccines

KemPharm submits IND application for ADHD candidate KP-484

Nationwide Children's Hospital patents gene therapy targeting DUX4

INSERM and collaborators describe antibodies targeting B- and T-lymphocyte attenuator

The University of Szeged identifies new alpha-7 nicotinic receptor agonists

Patrys presents first preclinical data for PAT-DX1-NP

Positive topline data from APOLLO phase III trial of patisiran

Sponge derivative oscarellin has anti-inflammatory, antidiabetic activity

AltImmune cleared to begin phase II study of NasoVAX flu vaccine

Glythera enters antibody agreement with Iontas

Novel ACADVL gene mutation discovered for VLCADD

Bavencio approved in E.U. for metastatic Merkel cell carcinoma

PRX-ASL from PhaseRx obtains FDA orphan status for ASLD

Hemophilia gene therapy SHP-654 receives FDA orphan drug designation

BMS-986226 studied alone and in combination with nivolumab or ipilimumab for solid tumors

LifeMine Therapeutics closes series A financing

New mutation in PDE12 gene causing lethal lactic acidosis discovered

Protagonist Therapeutics reports initial results from phase I trial of PTG-300

Pendopharm invests in Edesa Biotech and licenses three anorectal treatments

FDA awards regenerative medicine advanced therapy designation to ATIR-101

Bavarian Nordic reports 6-month follow-up data from phase II trial of MVA-BN RSV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...